Zu den Inhalten springen

Abteilung Endokrinologie und DiabetologieKlinik für Innere Medizin II

Kontextnavigation:

Publikationen

Endokrinologie und Diabetologie
2014

2014

  • Laubner, K., Flohr, F., and Seufert, J. 2014. Nebennierenrinden (NNR)-Tumoren. In Das Rote Buch: Hämatologie und Internistische Onkologie. D.P. Berger, J. Duyster, M. Engelhardt, R. Engelhardt, H. Henß, and R. Mertelsmann, editors. Heidelberg, München, Landsberg, Frechen, Hamburg: ecomed MEDIZIN. 1000-1003.

  • Laubner, K., Flohr, F., and Seufert, J. 2014. Hypophysentumoren. In Das Rote Buch: Hämatologie und Internistische Onkologie. D.P. Berger, J. Duyster, M. Engelhardt, R. Engelhardt, H. Henß, and R. Mertelsmann, editors. Heidelberg, München, Landsberg, Frechen, Hamburg: ecomed MEDIZIN. 1004-1007.
2013

2013

  • Bausch, D., Keck, T., Laubner, K., Brass, V., Weber, W., and Seufert, J. 2013. Therapieschema neuroendokriner Tumoren [Therapy algorithm of neuroendocrine tumours]. Der Onkologe 19:216-217.

  • Christ, E., Wild, D., Ederer, S., Behe, M., Nicolas, G., Caplin, M.E., Brändle, M., Clerici, T., Fischli, S., Stettler, C., Ell, P.J., Seufert, J., Gloor, B., Perren, A., Reubi, J.C., and Forrer, F. 2013. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. Lancet Diabetes & Endocrinology 1:115-122.

  • Colao, A., De Block, C., Gaztambide, M.S., Kumar, S., Seufert, J., and Casanueva, F.F. 2013. Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations. Pituitary. DOI:10.1007/s11102-013-0483-3.

  • Gentzsch, S., Kern, J.S., Loeckermann, S., Geissler, E., Seufert, J., Bernard, C., Kohlhase, J., Bruckner-Tuderman, L., and Meiss, F. 2013. Iatrogenic Vitamin D Deficiency in a Patient with Gorlin Syndrome: The Conundrum of Photoprotection. Acta Derm Venereol. DOI: 10.2340/00015555-1714.

  • Konrad, K., Scheuing, N., Badenhoop, K., Borkenstein, M.H., Gohlke, B., Schofl, C., Seufert, J., Thon, A., and Holl, R.W. 2013. Cystic fibrosis-related diabetes compared with type 1 and type 2 diabetes in adults. Diabetes Metab Res Rev 29:568-575.

  • Laubner, K., Brass, V., Weber, W., and Seufert, J. 2013. Aktuelle Diagnostik und Therapie von gastroenteropankreatischen neuroendokrinen Tumoren (GEP-NET) [Current diagnostics and therapy of gastroenteropancreatic neuroendocrine tumors (GEP-NET)]. Der Onkologe 19:218-223.

  • Laubner, K., Molz, K., Kerner, W., Karges, W., Lang, W., Dapp, A., Schütt, M., Best, F., Seufert, J., and Holl, R.W. 2013. Daily Insulin Doses and Injection Frequencies of Neutral Protamine Hagedorn (NPH) Insulin, Insulin Detemir and Glargine in Type 1 and Type 2 Diabetes: A Multicenter Analysis of 51 964 Patients from the German/Austrian DPV-Wiss Database. Diabetes Metab Res Rev.

  • Laubner, K., Thomusch, O., and Seufert, J. 2013. Tumoren der Nebenschilddrüse [Tumours of the parathyroid gland]. Der Onkologe 19:505-512.

  • Oehlke, O., Shah, M., Seufert, J., and Grosu, A.L. 2013. Multimodale Therapie von Hypophysenadenomen [Multimodal therapy of pituitary adenomas]. Der Onkologe 19:513-522.

  • Rosenstock, J., Rodbard, H.W., Bain, S.C., D'Alessio, D., Seufert, J., Thomsen, A.B., Svendsen, C.B., DeVries, J.H., and Liraglutide-Detemir Study, G. 2013. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. J Diabetes Complications 27:492-500.

  • Seufert, J., Brath, H., Pscherer, S., Borck, A., Bramlage, P., and Siegmund, T. 2013. Composite efficacy parameters and predictors of hypoglycaemia in basal-plus insulin therapy-a combined analysis of 713 type 2 diabetic patients. Diabetes Obes Metab. DOI:10.1111/dom.12211.

  • Seufert, J., and Gallwitz, B. 2013. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes Obes Metab.

  • Seufert, J., Pegelow, K., and Bramlage, P. 2013. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study. Vasc Health Risk Manag 9:711-717.
2012

2012

  • Hunt, K. A., Smyth, D. J., Balschun, T., Ban, M., Mistry, V., Ahmad, T., Anand, V., Barrett, J. C., Bhaw-Rosun, L., Bockett, N. A. et al (Seufert, J. Collaborator) 2012. Rare and functional SIAE variants are not associated with autoimmune disease risk in up to 66,924 individuals of European ancestry. Nat. Genet. 44(1):3-5.

  • Schutt, M., Fach, E. M., Seufert, J., Kerner, W., Lang, W., Zeyfang, A., Welp, R., and Holl, R. W. 2012. Multiple complications and frequent severe hypoglycaemia in 'elderly' and 'old' patients with Type 1 diabetes. Diabet. Med 29(8):e176-e179.

  • Korsten-Reck, U., Seufert, J., Dickhuth, H. H., Schumacher, Y. O., and Konig, D. 2012. Hypogonadism and anemia in an athlete. Int J. Sports Med 33(2):154-156.

  • DeVries, J. H., Bain, S. C., Rodbard, H. W., Seufert, J., D'Alessio, D., Thomsen, A. B., Zychma, M., and Rosenstock, J. 2012. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care 35(7):1446-1454.

  • Perakakis, N., Danassi, D., Alt, M., Tsaroucha, E., Mehana, A. E., Rimmer, N., Laubner, K., Wang, H., Wollheim, C. B., Seufert, J. et al 2012. Human Kruppel-like factor 11 differentially regulates human insulin promoter activity in beta-cells and non-beta-cells via p300 and PDX1 through the regulatory sites A3 and CACCC box. Mol. Cell Endocrinol. 363(1-2):20-6.

  • Rischke, H. C., Benz, M. R., Wild, D., Mix, M., Dumont, R. A., Campbell, D., Seufert, J., Wiech, T., Rossler, J., Weber, W. A. et al 2012. Correlation of the Genotype of Paragangliomas and Pheochromocytomas with Their Metabolic Phenotype on 3,4-Dihydroxy-6-18F-Fluoro-L-Phenylalanin PET. J. Nucl. Med. 53(9):1352-8.

  • Seufert, J., Laubner, K., Weber, W., and Brass, V. 2012. Diagnose und Therapie neuroendokriner Tumoren. Onkologie heute 10(5):39-42.

  • Kenzel S., Mergen M., von Süßkind-Schwendi J., Wennekamp J., Deshmukh S. D., Haeffner M., Triantafyllopoulou A., Fuchs S., Farmand S., Santos-Sierra S., Seufert J., van den Berg T. K., Kuijpers T. W. and Henneke P. 2012. Insulin Modulates the Inflammatory Granulocyte Response to Streptococci via Phosphatidylinositol 3-Kinase. J Immunol. 189(9):4582-91.
2011

2011

  • Seufert, J. 2011. Addressing glycemic variation. Br.J.Diabetes Vasc.Dis. 11(Suppl 1):S2-S5.

  • Kuehnen, P., Laubner, K., Raile, K., Schöfl, C., Jakob, F., Pilz, I., Päth, G., and Seufert, J. 2011. Protein Phosphatase 1 (PP-1)-Dependent Inhibition of Insulin Secretion by Leptin in INS-1 Pancreatic Beta-Cells and Human Pancreatic Islets. Endocrinology. 152:1800-1808.

  • Vonend, O., Ockenfels, N., Gao, X., Allolio, B., Lang, K., Mai, K., Quack, I., Saleh, A., Degenhart, C., Seufert, J., et al. 2011. Adrenal Venous Sampling: Evaluation of the German Conn's Registry. Hypertension 57:990-995.

  • Limbert, C., Päth, G., Ebert, R., Rothhammer, V., Kassem, M., Jakob, F., and Seufert, J. 2011. PDX1- and NGN3-mediated in vitro reprogramming of human bone marrow-derived mesenchymal stromal cells into pancreatic endocrine lineages. Cytotherapy. 13(7):802-813.

  • Laubner, K., Weber, W., and Seufert, J. 2011. Graves' ophthalmopathy from the internist's perspective. Ophthalmologe 108:410-416.

  • Wild, D., Christ, E., Caplin, M. E., Kurzawinski, T. R., Forrer, F., Brandle, M., Seufert, J., Weber, W. A., Bomanji, J., Perren, A., Ell, P. J., and Reubi, J. C. 2011. Glucagon-like Peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J.Nucl.Med 52(7):1073-1078.

  • Fliser, D., Dellanna, F., Koch, M., Seufert, J., Witzke, O., and Hauser, I. A. 2011. The PRIMAVERA study protocol design: Evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non-anemic patients with chronic kidney disease. Contemp.Clin Trials 32(6):786-792.

  • Perakakis, N., Laubner, K., Keck, T., Steffl, D., Lausch, M., Meyer, P. T., Burger, D., Csanadi, A., and Seufert, J. 2011. Ectopic ACTH-syndrome due to a Neuroendocrine Tumour of the Appendix. Experimental and Clinical Endocrinology and Diabetes 119(9):525-529.

  • Seufert, J. 2011. Stem cell therapy. Prevention and treatment of type 1 diabetes. Diabetologe 7:595-599.

  • Schneider, H. J., Klotsche, J., Wittchen, H. U., Stalla, G. K., Schopohl, J., Kann, P. H., Kreitschmann-Andermahr, I., and Wallaschofski, H. (Seufert, J. Collaborator) 2011. Effects of growth hormone replacement within the KIMS survey on estimated cardiovascular risk and predictors of risk reduction in patients with growth hormone deficiency. Clin Endocrinol (Oxf) 75(6):825-830.

  • Seufert, J. 2011. Zukunftsaspekte. In Diabetologie in Klinik und Praxis. H.U.Häring, Gallwitz,B., Müller-Wieland,D., Usadel,K.H., and Mehnert,H., editors. Georg Thieme Verlag. Stuttgart, New York. 677-683.

  • Seufert, J. 2011. Typ-1-Diabetes – sind Stammzellen bereits eine Option? Diabetologische Nachrichten.

  • Seufert, J. 2011. Sprechstunde Stammzellen. Diabetes Ratgeber 04/2011, 51.

  • Limbert, C., Päth, G., Ebert, R., Rothhammer, V., Kassem, M., Jakob, F., and Seufert, J. 2011. PDX1- and NGN3-mediated in vitro reprogramming of human bone marrow-derived mesenchymal stromal cells into pancreatic endocrine lineages. Cytotherapy. Epub ahead of print

  • Laubner, K., Weber, W., and Seufert, J. 2011. Graves' ophthalmopathy from the internist's perspective. Ophthalmologe 108:410-416.

  • Vonend, O., Ockenfels, N., Gao, X., Allolio, B., Lang, K., Mai, K., Quack, I., Saleh, A., Degenhart, C., Seufert, J., et al. 2011. Adrenal Venous Sampling: Evaluation of the German Conn's Registry. Hypertension 57:990-995.

  • Kuehnen, P., Laubner, K., Raile, K., Schöfl, C., Jakob, F., Pilz, I., Päth, G., and Seufert, J. 2011. Protein Phosphatase 1 (PP-1)-Dependent Inhibition of Insulin Secretion by Leptin in INS-1 Pancreatic Beta-Cells and Human Pancreatic Islets. Endocrinology. 152:1800-1808.

  • Seufert, J. 2011. Addressing glycemic variation. Br.J.Diabetes Vasc.Dis. 11(Suppl 1):S2-S5.
2010

2010

  • Rosenstock, J., Inzucchi, S. E., Seufert, J., Fleck, P. R., Wilson, C. A., and Mekki, Q. 2010. Initial Combination Therapy with Alogliptin and Pioglitazone in Drug-Naive Patients With Type 2 Diabetes. Diabetes Care 33(11):2406-2408.

  • Chevalier, N., Udi, J., Sigler, M., Wolf, M. E., Heinz, J., Schmitt-Graeff, A. H., Seufert, J., Wasch, R., and Engelhardt, M. 2010. Interplay of Parathyroid hormone-related peptide (PTHrP), renal insufficiency and bulky disease in the pathogenesis of hypercalcemia in Hodgkin's lymphoma (HL). Eur.J.Haematol. 85(4):368-369.

  • Hilner, J. E., Perdue, L. H., Sides, E. G., Pierce, J. J., Wagner, A. M., Aldrich, A., Loth, A., Albret, L., Wagenknecht, L. E., Nierras, C., and Akolkar, B., (Seufert, J. Collaborator) 2010. Designing and implementing sample and data collection for an international genetics study: the Type 1 Diabetes Genetics Consortium (T1DGC). Clin Trials 7(1 Suppl):S5-S32.

  • Seufert, J., Päth, G., Feilen, P., Hopt, U., Krautz, C., Saeger, I., Schröder, I., Kragl, M., Wobus, A. M., Lammert, E., and Solimena, M. 2010. Mechanisms and methods for regeneration and replacement of insulin producing pancreatic beta cells in diabetes mellitus. Med. Welt 61:87-93.

  • Seufert, J. 2010. Pioglitazone-Metformin Extended-Release Fixed-Dose Combination for the Treatment of Type 2 Diabetes. Clin.Med.Rev.Vasc.Health 2:1-15.

  • Schäfer, A., Scheurlen, M., Seufert, J., Keicher, C., Weissbrich, B., Rieger, P., and Kraus, M. R. 2010. Platelet serotonin (5-HT) levels in interferon-treated patients with hepatitis C and its possible association with interferon-induced depression. J.Hepatol. 52(1):10-15.

  • Seufert, J. 2010. Diabetestherapie der Zukunft-Von innovativen Medikamenten bis zur Stammzelle. Jatros. Diabetes&Stoffwechsel 01/2010.

  • Limbert, C., Ebert, R., Schilling, T., Päth, G., Benisch, P., Klein-Hitpass, L., Seufert, J., and Jakob, F. 2010. Functional signature of human islet-derived precursor cells compared to bone marrow-derived mesenchymal stem cells. Stem Cells Dev. 19(5):679-691.

  • Flohr, F., Reincke, M., and Seufert, J. 2010. Nebennierenrinden (NNR)-Tumoren. In Das Rote Buch: Hämatologie und Internistische Onkologie. D.P.Berger, Engelhardt,R., and Mertelsmann,R., editors. ecomed Medizin. Landsberg/Lech. 942-944.

  • Flohr, F., Reincke, M., and Seufert, J. 2010. Hypophysen-Tumoren. In Das Rote Buch: Hämatologie und Internistische Onkologie. D.P.Berger, Engelhardt,R., and Mertelsmann,R., editors. ecomed Medizin. Landsberg/Lech. 945-948.

  • Seufert, J., and Rumberger, B. 2010. Hyperkalzämie. In Differenzialdiagnostik und Differenzialtherapie - Entscheidungen in der Inneren Medizin. R.Brunkhorst, and Schölmerich,J., editors. Urban & Fischer. München. 108-109.

  • Seufert, J., and Wollersen, K. 2010. Hypokalzämie. In Differenzialdiagnostik und Differenzialtherapie - Entscheidungen in der Inneren Medizin. R.Brunkhorst, and Schölmerich,J., editors. Urban & Fischer. München. 120-121.

  • Seufert, J., and Kaufmann, S. 2010. Nebenniereninzidentalom. In Differenzialdiagnostik und Differenzialtherapie - Entscheidungen in der Inneren Medizin. R.Brunkhorst, and Schölmerich,J., editors. Urban & Fischer. München. 172-173.

  • Seufert, J., and Flohr, F. 2010. Akromegalie. In Differenzialdiagnostik und Differenzialtherapie - Entscheidungen in der Inneren Medizin. R.Brunkhorst, and Schölmerich,J., editors. Urban & Fischer. München. 262-263.

  • Seufert, J., and Hansen, I. 2010. Hypophyseninsuffizienz. In Differenzialdiagnostik und Differenzialtherapie - Entscheidungen in der Inneren Medizin. R.Brunkhorst, and Schölmerich,J., editors. Urban & Fischer. München. 348-349.

  • Seufert, J., and Lichtenauer, U. 2010. Nebennierenrindeninsuffizienz. In Differenzialdiagnostik und Differenzialtherapie - Entscheidungen in der Inneren Medizin. R.Brunkhorst, and Schölmerich,J., editors. Urban & Fischer. München. 400-401.

  • Seufert, J., and Laubner, K. 2010. Phäochromozytom. In Differenzialdiagnostik und Differenzialtherapie - Entscheidungen in der Inneren Medizin. R.Brunkhorst, and Schölmerich,J., editors. Urban & Fischer. München. 418-419.
2009

2009

  • Schernthaner, G., Barnett, A. H., Betteridge, D. J., Carmena, R., Ceriello, A., Charbonnel, B., Hanefeld, M., Lehmann, R., Malecki, M. T., Nesto, R., Pirags, V., Scheen, A., Seufert, J., Sjoholm, A., Tsatsoulis, A., and Defronzo, R. 2010. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 53(7):1258-1269.

  • Zhang, H., Ables, E. T., Pope, C. F., Washington, M. K., Hipkens, S., Means, A. L., Path, G., Seufert, J., Costa, R. H., Leiter, A. B., Magnuson, M. A., and Gannon, M. 2009. Multiple, temporal-specific roles for HNF6 in pancreatic endocrine and ductal differentiation. Mech.Dev. 126(11-12):958-973.

  • Buchfelder, M., Schlaffer, S., Droste, M., Mann, K., Saller, B., Brubach, K., Stalla, G. K., Strasburger, C. J., and Seufert, J. 2009. The German ACROSTUDY: past and present. Eur. J. Endocrinol 161 Suppl 1:S3-S10.

  • Buchfelder, M., Weigel, D., Droste, M., Mann, K., Saller, B., Brubach, K., Stalla, G. K., Bidlingmaier, M., Strasburger, C. J., and Seufert, J. 2009. Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur. J. Endocrinol 161(1):27-35.

  • Seufert, J. 2009. Glucose self-monitoring: an end in itself or the Holy Grail? Dtsch Arztebl Int 106(37):585-586.

  • Limbert, C. and Seufert, J. 2009. In vitro (re)programming of human bone marrow stromal cells toward insulin-producing phenotypes. Pediatr.Diabetes 10(6):413-419.

  • Schirpenbach, C., Segmiller, F., Diederich, S., Hahner, S., Lorenz, R., Rump, L. C., Seufert, J., Quinkler, M., Bidlingmaier, M., Beuschlein, F., Endres, S., and Reincke, M. 2009. The diagnosis and treatment of primary hyperaldosteronism in Germany: results on 555 patients from the German Conn Registry. Dtsch Arztebl Int 106(18):305-311.

  • Al-Taie, O. H., Graf, T., Illert, B., Katzenberger, T., Mork, H., Kraus, M. R., Barthelmes, H. U., Scheurlen, M., and Seufert, J. 2009. Differential effects of PPARgamma activation by the oral antidiabetic agent pioglitazone in Barrett's carcinoma in vitro and in vivo. J.Gastroenterol. 44(9):919-929.

  • Hefner, J., Csef, H., and Seufert, J. 2009. [Kallmann syndrome. Fundamentals and two medical histories]. Nervenarzt 80(10):1169-5.

  • Hefner, J., Csef, H., and Seufert, J. 2009. [Kallmann syndrome--a form of hypogonadotropic hypogonadism]. Deutsche Medizinische Wochenschrift 134(22):1157-1160.

  • Seufert, J. 2009. The backbone of oral glucose-lowering therapy: time for a paradigm shift? Fundam.Clin Pharmacol. 23(6):651-667.

  • Schernthaner, G., Forst, T., Gulba, D., Haberbosch, W., Hanefeld, M., Linss, G., Marz, W., Mehnert, H., Rosak, C., Schnell, O., Seufert, J., Tschope, D., and Erdmann, E. 2009. [Challenge in diabetes therapy: effects of glitazones beyond blood glucose control]. Deutsche Medizinische Wochenschrift 134(18):949-954.

  • Goebel, S., Lienau, J., Rammoser, U., Seefried, L., Wintgens, K. F., Seufert, J., Duda, G., Jakob, F., and Ebert, R. 2009. FGF23 is a putative marker for bone healing and regeneration. J.Orthop.Res 27(9):1141-1146.

  • Born-Frontsberg, E., Reincke, M., Rump, L. C., Hahner, S., Diederich, S., Lorenz, R., Allolio, B., Seufert, J., Schirpenbach, C., Beuschlein, F., Bidlingmaier, M., Endres, S., and Quinkler, M. 2009. Cardio- and cerebrovascular comorbidites of hypo- and normokalemic primary aldosteronism: results of the German Conn's Registry. J.Clin Endocrinol Metab 94(4):1125-1130.

  • Reincke, M., Rump, L. C., Quinkler, M., Hahner, S., Diederich, S., Lorenz, R., Seufert, J., Schirpenbach, C., Beuschlein, F., Bidlingmaier, M., Meisinger, C., Holle, R., and Endres, S. 2009. Risk Factors Associated with a Low Glomerular Filtration Rate in Primary Aldosteronism. J.Clin Endocrinol Metab 94(3):869-875.
2008

2008

  • Seufert, J. 2008. Potenzielle neue Option für die Zelltherapie-Reprogrammierung von exokrinen Pankreas- zu Betazellen [New potential options for cell therapy-Reprogramming of pancreatic exocrine to beta cells]. INFO Diabetologie 2(6):24-25.

  • Seufert, J. 2008. Pankreasinseltransplantatation bei Typ-1-Diabetes: Spezielle Begleitmedikation erhöht Chance auf mehr Erfolg pro Spender [Pancreatic islet transplantation: Specific comedication increases success rate]. INFO Diabetologie 2(5):32-33.

  • Seufert, J. 2008. Insulinwirkung im Gehirn zieht im Körper weite Kreise - Neue Ansatzpunkte für die Therapie? [Brain insulin action affects the whole body - New options for treatment?]. INFO Diabetologie. 2(4):20-21.

  • Fujita, Y., Chui, J. W. , King, D. S., Zhang, T., Seufert, J., Pownall, S., Cheung, A. T., and Kieffer, T. J. 2008. Pax6 and Pdx1 are required for production of glucose-dependent insulinotropic polypeptide (GIP) in proglucagon expressing L-cells. Am.J.Physiol Endocrinol Metab. 295:E648-E657.

  • Seufert, J. 2008. [ACCORD (Action to Control Cardiovascular Risk in Diabetes trial) becoming "two-tone"]. Dtsch.Med Wochenschr. 133 (20):1068-1070.

  • Flohr, F., Harder, J., Seufert, J., Blum, H. E., and Spangenberg, H. C. 2008. Hypothyroidism in patients with hepatocellular carcinoma treated by transarterial chemoembolization. Hepatology. 47(6):2144.

  • Duerschmied, D., Maletzki, P., Freund, G., Olschewski, M., Seufert, J., Bode, C., and Hehrlein, 2008. Analysis of muscle microcirculation in advanced diabetes mellitus by contrast enhanced ultrasound. Diabetes Res Clin Pract. 81:88-92.

  • Seufert, J. 2008. Diabetestherapie mit Gliptinen - Ein neues orales Wirkprinzip [Gliptins - a novel mode of action for oral antidiabetic drugs]. INFO Diabetologie 2(2):48-52.

  • Seufert, J. 2008. Fettzellen fördern die Insulinsekretion über die Ausschüttung von Visfatin [Adipocytes stimulate insulin secretion by visfatin]. INFO Diabetologie 2(1):2-3.

  • Seufert, J. 2008. Gestörte Leptinwirkung an Betazellen fördert Typ-2-Diabetes bei Adipositas [Leptin resistance in pancreatic beta cells in obesity leads to type 2 diabetes]. INFO Diabetologie 2(1):6-7.

  • Seufert, J. 2008. Adulte Stammzellen des Pankreas können Betazellen ersetzen [Adult stem cells can replenish pancreatic beta cells]. INFO Diabetologie 2(3):44-45.

  • Seufert, J. 2008. Metabolischer Stress bedingt kognitive Störungen [Metabolic stress causes cognitive dysfunction in diabetes]. INFO Diabetologie 2(3):16-18.

  • Limbert, C., Päth, G., Jakob, F., and Seufert, J. 2008. Beta-cell replacement and regeneration: Strategies of cell-based therapy for type 1 diabetes mellitus. Diabetes Res Clin Pract. 79(3):389-399.

  • Seufert, J. and Urquhart, R. 2008. 2-Year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with Type 2 diabetes. Diabetes Res Clin.Pract. 79(3):453-460.

  • Kabitz, H. J., Sonntag, F., Walker, D., Schwoerer, A., Walterspacher, S., Kaufmann, S., Beuschlein, F., Seufert, J., and Windisch, W. 2008. Diabetic polyneuropathy is associated with respiratory muscle impairment in type 2 diabetes. Diabetologia 51(1):191-197.
2007

2007

  • Schäfer, A., Wittchen, H. U., Seufert, J., and Kraus, M. 2007. Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review. Int.J.Methods Psychiatr.Res. 16(4):186-201.

  • Li, Y. M., Schilling, T., Benisch, P., Zeck, S., Meissner-Weigl, J., Schneider, D., Limbert, C., Seufert, J., Kassem, M., Schutze, N. et al 2007. Effects of high glucose on mesenchymal stem cell proliferation and differentiation. Biochem. Biophys. Res Commun. 363(1):209-215.

  • Seufert, J. 2007. Osteocalcin regelt Glukosestoffwechsel [Osteocalcin regulates glucose metabolism]. INFO Diabetologie 1(1):6.

  • Flohr, F. and Seufert, J. 2007. Pituitary and adrenal gland surgery. Internist (Berl) 48(6):578-585.

  • Niu, X., Perakakis, N., Laubner, K., Limbert, C., Stahl, T., Brendel, M. D., Bretzel, R. G., Seufert, J., and Päth, G. 2007. Human Kruppel-like factor 11 inhibits human proinsulin promoter activity in pancreatic beta cells. Diabetologia 50(7):1433-1441.

  • Baumann, B., Seufert, J., Rolf, O., Jakob, F., Goebel, S., Eulert, J., and Rader, C. P. 2007. Upregulation of LITAF mRNA expression upon exposure to TiAlV and polyethylene wear particles in THP-1 macrophages. Biomed.Tech.(Berl) 52(2):200-207.

  • Laubner, K. and Seufert, J. 2007. Pharmaceutical therapy of diabetes mellitus type 2. Internist (Berl) 48(3):297-310.

  • Seufert, J. 2007. Macrovascular secondary prevention with pioglitazone in diabetics. PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events). Internist (Berl) 48(1):89-91.

  • Stork, S., Bots, M. L., Angerer, P., von, Schacky C., Grobbee, D. E., Angermann, C. E., and Seufert, J. 2007. Low levels of adiponectin predict worsening of arterial morphology and function. Atherosclerosis 194(2):e147-e153.

  • Watermann, I., Gerspach, J., Lehne, M., Seufert, J., Schneider, B., Pfizenmaier, K., and Wajant, H. 2007. Activation of CD95L fusion protein prodrugs by tumor-associated proteases. Cell Death.Differ. 14(4):765-774.
2006

2006

  • Schöttker, B., Heinz, W., Weissinger, F., Sozener, K., Eck, M., and Seufert, J. 2006. Parathyroid hormone-related protein-associated Hypercalcemia in a Patient with CLL type low grade leukemic B-cell lymphoma. Haematologica 91(12 Suppl):ECR45.

  • Seufert, J. 2006. Diabetesursachen-Regulation der Betazellmasse. Diabetologie und Stoffwechsel 1(5):288-292.

  • Seufert, J. 2006. A fixed-dose combination of pioglitazone and metformin: a promising alternative in metabolic control. Curr Med Res Opin 22(Suppl. 2):39-48.

  • Path, G., Opel, A., Gehlen, M., Rothhammer, V., Niu, X., Limbert, C., Romfeld, L., Hugl, S., Knoll, A., Brendel, M. D., Bretzel, R. G., and Seufert, J. 2006. Glucose-dependent expansion of pancreatic beta-cells by the protein p8 in vitro and in vivo. Am.J.Physiol Endocrinol.Metab 291(6):E1168-E1176.

  • Ebert, R., Vogelsang, A., Mandery, K., Seufert, J., and Jakob, F. 2006. Erbliche und erworbene Erkrankungen des Phosphatstoffwechsels, [Hereditary and aquired disorders of phosphate metabolism]. Osteol. 15:33-42.

  • Seufert, J. 2006. Cardiovascular outcome studies in type 2 diabetes therapy. Dtsch.Ärztebl. 103(14):A 934-A 942.

  • Jakob, F., Ebert, R., and Seufert, J. 2006. Fibroblast Growth Factor 23. AfCS-Nature Molecule Pages doi:10.1038/mp.a003934.01. Nature Publishing Group.

  • Päth, G., Limbert, C., and Seufert, J. 2006. (Stamm-)Zelltherapie des Diabetes mellitus: Aktuelle Aspekte. Diabetes, Stoffwechsel und Herz 1(1):65-74.
2005

2005

  • Laubner, K., Kieffer, T.J., Lam, N.T., Niu, X., Jakob, F., and Seufert, J. 2005. Inhibition of Preproinsulin Gene Expression by Leptin Induction of Suppressor of Cytokine Signaling 3 in Pancreatic Beta-Cells. Diabetes 54:3410-3417.

  • Baumann, B., Seufert, J., Jakob, F., Noth, U., Rolf, O., Eulert, J., and Rader, C.P. 2005. Activation of NF-kappaB signalling and TNFalpha-expression in THP-1 macrophages by TiAlV- and polyethylene-wear particles. J.Orthop.Res. 23(6):1241-1248.

  • Kraus, M.R., Schäfer, A., Bentink, T., Scheurlen, M., Weißbrich, B., Al-Taie, O., and Seufert, J. 2005. Sexual dysfunction in males with chronic hepatitis C and antiviral therapy: Interferon-induced functional androgen deficiency or depression? J.Endocrinol. 185,345-352.
2004

2004

  • Baumann, B., Rader, C.P., Seufert, J., Noth, U., Rolf, O., Eulert, J., and Jakob, F. 2004. Effects of polyethylene and tiAIV wear particles on expression of RANK, RANKL and OPG mRNA. Acta Orthop.Scand. 75(3):295-302.

  • Seufert, J., Lubben, G., Dietrich, K., and Bates, P.C. 2004. A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus. Clin.Ther. 26(6):805-818.

  • Seufert, J. 2004. Zelltransplantation und Gentransfer: Diabetestherapie der Zukunft? [Cell Therapy and Gene Therapy in Diabetes Mellitus]. MMW-Fortschr.Med. 146(20):39-40.

  • Fischbach, C., Seufert, J., Staiger, H., Hacker, M., Neubauer, M., Gopferich, A., and Blunk, T. 2004. Three-dimensional in vitro model of adipogenesis: comparison of culture conditions. Tissue Eng 10(1-2):215-229.

  • Seufert, J. 2004. Leptin Effects on Pancreatic beta-Cell Gene Expression and Function. Diabetes 53 Suppl 1,S152-S158.

  • Path, G., Opel, A., Knoll, A., and Seufert, J. 2004. Nuclear Protein p8 Is Associated With Glucose-Induced Pancreatic beta-Cell Growth. Diabetes 53 Suppl 1,S82-S85.
2003 - 1992

2003

  • Al Taie, O.H., Seufert, J., Karvar, S., Adolph, C., Mork, H., Scheurlen, M., Kohrle, J., and Jakob, F. 2003. Selenium supplementation enhances low selenium levels and stimulates glutathione peroxidase activity in peripheral blood and distal colon mucosa in past and present carriers of colon adenomas. Nutr.Cancer 46(2):125-130.

  • Seufert, J. 2003. Adipositas - eine genetisch bedingte Erkrankung? Genetische Grundlagen der Adipositas [Obesity - a genetic disease? Genetic bases of obesity]. Verhaltenstherapie & psychosoziale Praxis 35(3):517-529.

  • Päth, G. and Seufert, J. 2003. Zelltherapeutische Strategien für die Behandlung des Diabetes mellitus Typ 1 - Von der Inseltransplantation zur Stammzelltherapie [Novel Cell Therapy for the Treatment of Diabetes Mellitus Type 1 - From Islet Transplantation to Stem Cell Therapy]. Dtsch Ärztebl 100(23):A 1604-A 1611.

  • Päth, G. and Seufert, J. 2003. Current Status and Perspectives of Stem Cell Therapy for the Treatment of Diabetes mellitus. Med.Klin. 98(5):277-282.

  • Osterhoff, M., Mohlig, M., Schwanstecher, M., Seufert, J., Ortmann, J., Schatz, H., and Pfeiffer, A.F. 2003. Ca(2+)/calmodulin-dependent protein kinase II delta(2) regulates gene expression of insulin in INS-1 rat insulinoma cells. Cell Calcium 33(3):175-184.

2002

  • Seufert, J. 2002. Neue orale Antidiabetika für die Behandlung des Diabetes mellitus Typ 2 - Gegenwart und Zukunftsperspektiven. Med Welt 53,273-279.

  • Seufert, J. 2002. Do we need new ways of cell and gene treatment of diabetics? - Pro. Dtsch.Med.Wochenschr. 127(18):978.

  • Seufert, J. and Jakob, F. 2002. Gegenwart und Zukunft der Therapie mit oralen Antidiabetika. [Present and Future Therapy with Oral Antidiabetics]. Der Bay.Int. 22(5):282-292.

  • Rader, C.P., Baumann, B., Rolf, O., Radke, S., Hendrich, C., Schütze, N., Seufert, J., and Jakob, F. 2002. Detection of differentially expressed genes in particle disease using array-filter analysis. Biomed.Technik 47,111-116.

  • Al-Taie, O., Seufert, J., Mörk, H., Treis, H., Mentrup, B., Thalheimer, A., Starostik, P., Abel, J., Scheurlen, M., Köhrle, J., and Jakob, F. 2002. A complex DNA-repeat structure within the selenoprotein P promoter contains a functionally relevant polymorphism and is genetically unstable under conditions of mismatch repair deficiency. Eur.J.Hum.Gen. 10,499-504.

2001

  • Seufert, J., Ebert, K., Müller, J., Eulert, J., Hendrich, C., Werner, E., Schütze, N., Schulz, G., Kenn, W., Richtmann, H., Palitzsch, K.D., and Jakob, F. 2001. Octreotide Therapy for Tumor-Induced Osteomalacia. N.Engl.J.Med. 345(26):1883-1888.

  • Al-Taie, O., Mörk, H., Seufert, J., Treis, H., Jakob, F., and Scheurlen, M. 2001. Hereditäres Non-Polyposis Kolorektales Karzinom (HNPCC) - Aktuelle Übersicht zur Ätiologie, Klinik, Diagnostik und Therapie. Med.Klin. 96(9):529-538.

2000

  • Lechner, A., Schutze, N., Siggelkow, H., Seufert, J., and Jakob, F. 2000. The immediate early gene product hCYR61 localizes to the secretory pathway in human osteoblasts. Bone 27(1):53-60.

1999

  • Seufert, J. 1999. [The significance of direct effects of leptin at the endocrine pancreas for the pathogenesis of diabetes mellitus type 2]. Dtsch.Med.Wochenschr. 124(28/29):A17-A18.

  • Seufert, J. 1999. [The significance of leptin for the pathogenesis of diabetes mellitus type 2. Direct effects on endocrine pancreas]. Internist.(Berl.) 40(8):894-897.

  • Seufert, J., Kieffer, T.J., Leech, C.A., Holz, G.G., Moritz, W., Ricordi, C., and Habener, J.F. 1999. Leptin suppression of insulin secretion and gene expression in human pancreatic islets: implications for the development of adipogenic diabetes mellitus. J.Clin.Endocrinol.Metab. 84(2):670-676.

  • Seufert, J., Kieffer, T.J., and Habener, J.F. 1999. Leptin inhibits insulin gene transcription and reverses hyperinsulinemia in leptin-deficient ob/ob mice. Proc.Natl.Acad.Sci.U.S.A. 96(2):674-679.

  • Ebert-Dumig, R., Seufert, J., Schneider, D., Kohrle, J., Schutze, N., and Jakob, F. 1999. [Expression of selenoproteins in monocytes and macrophages-- implications for the immune system]. Med.Klin. 94 Suppl 3:29-34(Suppl. 3):29-34.

1998

  • Seufert, J., Weir, G.C., and Habener, J.F. 1998. Differential expression of the insulin gene transcriptional repressor CCAAT/enhancer-binding protein beta and transactivator islet duodenum homeobox-1 in rat pancreatic beta cells during the development of diabetes mellitus. J.Clin.Invest. 101(11):2528-2539. 

1997

  • Lu, M., Seufert, J., and Habener, J.F. 1997. Pancreatic beta-cell-specific repression of insulin gene transcription by CCAAT/enhancer-binding protein beta. Inhibitory interactions with basic helix-loop-helix transcription factor E47. J.Biol.Chem. 272(45):28349-28359.

1995

  • Jakob, F., Homann, D., Seufert, J., Schneider, D., and Kohrle, J. 1995. Expression and regulation of aromatase cytochrome P450 in THP 1 human myeloid leukaemia cells. Mol.Cell.Endocrinol. 110(1-2):27-33.

1994

  • Jakob, F., Seufert, J., Sarrazin, C., Schneider, D., Kohrle, J., and Tony, H.P. 1994. Topoisomerase I-inhibition enhances vitamin D-responsive expression of the receptor for lipopolysaccharide binding protein CD 14. Biochem.Biophys.Res.Commun. 199(2):531-539.

1993

  • Jakob, F., Seufert, J., Haack, D., Schroder, K., Ludwig, J., Rendl, J., and Vecsei, P. 1993. [Unilateral autonomous aldosterone production in hyperaldosteronism suppressible by dexamethasone]. Dtsch.Med.Wochenschr. 118(50):1837-1843.

  • Hiddemann, W., Unterhalt, M., Pott, C., Wormann, B., Sandford, D., Freund, M., Engert, A., Gassmann, W., Holtkamp, W., and Seufert, J. 1993. Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group. Semin.Oncol. 20(5 Suppl 7):28-31.

1992

  • Jakob, F., Gieseler, F., Tresch, A., Hammer, S., Seufert, J., and Schneider, D. 1992. Kinetics of nuclear translocation and turnover of the vitamin D receptor in human HL60 leukemia cells and peripheral blood lymphocytes-- coincident rise of DNA-relaxing activity in nuclear extracts. J.Steroid Biochem.Mol.Biol. 42(1):11-16.

Klinik für Innere Medizin II

Abteilung
Endokrinologie und Diabetologie

Hugstetter Straße 55
79106 Freiburg

Ambulanz:   0049-(0)761 270-35120
Sekretariat: 0049-(0)761 270-34200
Telefax:        0049-(0)761 270-34130
E-Mail:          office-seufert.med
                       @uniklinik-freiburg.de